Abcam Intelligence Profile

abcam.comLast reviewed: October 20, 2026Research coverage: 94%

Overall data confidence:Unknown

Identity confidence

High

9 of 10 identity fields independently documented

Corporate continuity

Continuous since 1998; abcam.com is the primary global storefront; the former investor-relations site (abcamplc.com) was used while the company was listed.

Based on domain history and corporate record fields

Regulatory exposure

None identified

Derived from published risk flags

Evidence integrity

High

6 of 7 testing fields documented

Transaction transparency

High

5 of 5 commercial fields documented

Change activity

None tracked

0 change events tracked

Research Incomplete

Research coverage for this vendor is 94%. Our research on Abcam remains incomplete — what we have verified so far is published below, and research is continuing.

Still to research:

Public summary reviewed

Overview#

Abcam Ltd (England, company No. 03509322, incorporated 12 February 1998; HQ Discovery Drive, Cambridge Biomedical Campus, Cambridge, UK; U.S. office in Waltham, MA) has been a Danaher Corporation operating company since December 2023. It sells catalog peptides and blocking peptides and offers customized peptide synthesis (modifications and conjugations) within a much larger antibody/reagent catalog; all products are research-use-only. Identity is verified from the vendor's own Terms of Sale (which name Abcam Ltd and its registered office) and the Companies House record. All defined regulatory searches (FDA warning letters, recalls, import alerts, FTC, state AG, civil litigation, criminal/injunctive) returned No Record Found in the defined search. The material open item is evidence consistency: the August 2026 independent report flags 185 validation images across 115 Abcam antibody products — allegation-level, antibodies not peptides, vendor review underway. Policies are unusually explicit (30-day invoice terms; credit card/cheque/bank/wire payment; 20% restocking on incorrect orders; Product Promise replacement/refund). Registered agent (U.S. subsidiary) and test recency are Unknown. No High/Critical findings.

Company Identity#

Vendor Brand NameAbcam

HighSource: Abcam — Peptides and blocking peptides product category

Primary Website Domainabcam.com

ModerateSource: Abcam — official website (intake domain confirmation)

Legal Entity NameAbcam Ltd — company registered in England under company number 03509322; a Danaher Corporation company

HighSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

State of RegistrationEngland and Wales (United Kingdom)

HighSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Entity StatusActive (Companies House: ABCAM LIMITED — Active, private limited company)

HighSource: Companies House record via Clarity Project — ABCAM LIMITED No. 03509322, Active, incorporated 12 Feb 1998, registered office Discovery Drive, Cambridge Biomedical Campus, CB2 0AX

Incorporation / Formation Date1998-02-12

HighSource: Companies House record via Clarity Project — ABCAM LIMITED No. 03509322, Active, incorporated 12 Feb 1998, registered office Discovery Drive, Cambridge Biomedical Campus, CB2 0AX

Named Principals / ManagersAlan Hirzel — Chief Executive Officer at the time of the Danaher acquisition (2023). Founder: Jonathan Milner (historical CEO).

ModerateSource: Abcam press release — Danaher to Acquire Abcam ($24.00/share; ~$5.7B enterprise value)

Registered AgentNot independently verified

UnknownSource: Companies House record via Clarity Project — ABCAM LIMITED No. 03509322, Active, incorporated 12 Feb 1998, registered office Discovery Drive, Cambridge Biomedical Campus, CB2 0AX

Operating AddressRegistered office / HQ: Discovery Drive, Cambridge Biomedical Campus, Cambridge CB2 0AX, UK. U.S. office: 152 Grove Street, Building 1100, Waltham, MA 02453, USA.

HighSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Address ConsistencyConsistent — the Discovery Drive, Cambridge Biomedical Campus address appears in the Companies House record, the 2020 annual report, SEC filings and the current Terms of Sale; the Waltham, MA address appears in 2023 SEC acquisition documents.

HighSource: Companies House record via Clarity Project — ABCAM LIMITED No. 03509322, Active, incorporated 12 Feb 1998, registered office Discovery Drive, Cambridge Biomedical Campus, CB2 0AX

Domain and Digital Identity#

Domain Registration Date1998-03-30

HighSource: Verisign RDAP — abcam.com

Domain Ownership / Registrar Change HistoryRegistrar: Network Solutions, LLC; RDAP record last changed 2024-03-29; long registration horizon (to 2034); registrant redacted. No transfer or impersonation signals; domain creation matches the company's 1998 founding era.

ModerateSource: Verisign RDAP — abcam.com

Website ContinuityContinuous since 1998; abcam.com is the primary global storefront; the former investor-relations site (abcamplc.com) was used while the company was listed.

ModerateSource: Verisign RDAP — abcam.com

Contact Channel IntegrityPublished HQ phone +44 (0)1223 696000 (Cambridge) and support channels via abcam.com; U.S. customers are served via the Waltham, MA office. No conflicting third-party contact details identified.

ModerateSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Regulatory and Legal History#

FDA Warning Letter HistoryNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FDA Recall / Safety Action HistoryNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FDA Import Alert / Detention ExposureNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

FTC Enforcement HistoryNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

State Regulatory / Attorney General ActionsNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Relevant Civil LitigationNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Criminal / Injunctive ProceedingsNo Record Found in the defined search

ModerateSource: Defined web search — no record naming the vendor found

Testing and COA Evidence#

Public COA AvailabilityPer-product datasheets are published on abcam.com for catalog items (identified by ab-number), including the peptides and blocking peptides range; no separate public per-lot COA library was identified — conformance is backed by the vendor's Product Promise (Terms of Sale §5.6).

ModerateSource: Abcam — Peptides and blocking peptides product category

Batch / Lot SpecificityPartially established — products are identified by catalog (ab) number; lot-specific performance information is handled through datasheets and technical support rather than a public lot-lookup COA portal.

LowSource: Abcam — Peptides and blocking peptides product category

Independent Laboratory IdentityIn-house validation — the vendor states its scientists conduct internal validation for in-house generated products and review data images provided externally; no independent third-party laboratory is named.

ModerateSource: Reese Richardson — At least 15 companies are selling antibodies using faked validation data (Aug 2026)

COA Verification StatusNo independent COA verification channel; quality assurance rests on the vendor's Product Promise — if a product does not conform to datasheet specifications, replacement or refund is offered (contact within 12 months of delivery per the returns policy).

ModerateSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Test RecencyNot independently verified

UnknownSource: Abcam — Peptides and blocking peptides product category

Testing CoverageCatalog peptides and blocking peptides are sold to datasheet specifications; the Functional Peptides line states that customized peptide synthesis services, including modifications and conjugations, are available. All products are marked 'For research use only. Not for use in diagnostic or therapeutic procedures.'

ModerateSource: Abcam — Peptides and blocking peptides product category

Evidence ConsistencyLargest count in the August 2026 independent report (Reese Richardson): 185 images across 115 Abcam products flagged for duplicated/manipulated validation-image backgrounds. Abcam responded that in-house products are internally validated, externally provided images are reviewed, concerns are investigated against original data, and images are removed where originals are unavailable; a review is underway. One earlier flagged image was wordlessly removed while the product remained on sale. Allegation-level independent reporting (antibodies), not a regulatory finding.

ModerateSource: Reese Richardson — At least 15 companies are selling antibodies using faked validation data (Aug 2026)

Payment, Refund and Shipping#

Accepted Payment MethodsCredit card, cheque, bank and wire transfer (Terms of Sale §7.6). Invoices are payable in cleared funds no later than 30 days after the invoice date (§7.4).

HighSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Refund / Return PolicyIncorrectly ordered products: return at the vendor's discretion subject to a 20% restocking charge plus shipping/handling/packaging (§5.3); no returns of products with special shipping requirements (dry ice, hazardous) or custom products. Product Promise (§5.6): products not conforming to datasheet specifications are eligible for replacement or refund — per the returns policy, contact within 12 months of delivery, refunds issued within 21 business days; wrong-item returns require prior authorization and are shipped at the purchaser's expense within 7 business days. Damage/shortage claims must be notified within 7 days of delivery (§3.10).

HighSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Shipping & Fulfillment RepresentationsSame-day dispatch of in-stock products and FedEx premium delivery to 140+ countries (Product Promise page); delivery details and costs are confirmed during ordering and in the dispatch confirmation email (Terms §3).

ModerateSource: Abcam — Product Promise (same-day dispatch; FedEx premium delivery to 140+ countries)

Terms / Policy StabilityTerms of Sale are published on abcam.com's legal pages (version reviewed 2026-10-20); no abrupt changes observed in this intake pass.

LowSource: Abcam — Terms of Sale (Abcam Ltd, company No. 03509322, registered office Discovery Drive, Cambridge CB2 0AX; §5 returns/Product Promise; §7 payment)

Customer Complaint PatternResearcher-community criticism has long centered on antibody reproducibility; in 2026 the focal complaint is validation-image integrity (see evidence_consistency). No BBB/AG fraud or fulfillment complaint pattern was identified in the defined search.

ModerateSource: C&EN — New report suggests widespread image manipulation in antibody market (Aug 2026)

Material Changes#

No material changes recorded.

Sources#

Abcam — official website (intake domain confirmation)Tier 2 · Official/CommercialVendor Website

Retrieved: October 20, 2026